U.S. markets open in 6 hours 1 minute
  • S&P Futures

    3,796.25
    +5.75 (+0.15%)
     
  • Dow Futures

    30,818.00
    -10.00 (-0.03%)
     
  • Nasdaq Futures

    13,055.25
    +69.75 (+0.54%)
     
  • Russell 2000 Futures

    2,140.70
    -6.60 (-0.31%)
     
  • Crude Oil

    53.39
    +0.41 (+0.77%)
     
  • Gold

    1,853.40
    +13.20 (+0.72%)
     
  • Silver

    25.55
    +0.23 (+0.91%)
     
  • EUR/USD

    1.2148
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.0920
    0.0000 (0.00%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3673
    +0.0039 (+0.28%)
     
  • USD/JPY

    103.7540
    -0.1380 (-0.13%)
     
  • BTC-USD

    35,535.70
    -358.55 (-1.00%)
     
  • CMC Crypto 200

    704.37
    -10.82 (-1.51%)
     
  • FTSE 100

    6,710.42
    -2.53 (-0.04%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences

XOMA Corporation
·3 min read

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

  • H.C. Wainwright Virtual BioConnect 2021 Conference taking place January 11-14, 2021. XOMA’s presentation will be available on demand beginning January 11, 2021 at 6:00 AM ET and can be accessed at http://bit.ly/3hFUIaA.

  • Biotech Showcase Digital Conference taking place January 11-15, 2021. The Company’s presentation will be available to registered participants.

The presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. Replays of the presentations will be available and archived on the site for 90 days after the event.

About XOMA Corporation
XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. For more information, visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, creating additional value for the stockholders and cash sufficiency forecast. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of these assets will become commercially available.

Investor contact:
Juliane Snowden
Oratorium Group, LLC
+1 646-438-9754
jsnowden@oratoriumgroup.com

Media contact:
Kathy Vincent
KV Consulting & Management
+1 310-403-8951
kathy@kathyvincent.com